Department of Pharmacology and Pharmacogenomics Research Center; Department of Clinical Pharmacology, Inje University College of Medicine, Inje University Busan Paik Hospital, 633-165 Gaegum-dong, Jin-gu, Busan 614-735, South Korea; Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan, South Korea.
Department of Pharmacology and Pharmacogenomics Research Center; Department of Clinical Pharmacology, Inje University College of Medicine, Inje University Busan Paik Hospital, 633-165 Gaegum-dong, Jin-gu, Busan 614-735, South Korea.
Prostaglandins Leukot Essent Fatty Acids. 2018 Apr;131:6-13. doi: 10.1016/j.plefa.2018.02.003. Epub 2018 Mar 11.
CYP4F2 is an enzyme involved in the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid and metabolizes vitamin K into an inactive form. Our objectives were to identify new CYP4F2 genetic variants and to characterize the functional consequences of the conversion of arachidonic acid into 20-HETE. We used direct DNA sequencing to identify a total of 20 single-nucleotide polymorphisms (SNPs) including four coding variants, A27V, R47C, P85A, and V433M, in 50 randomly selected subjects. Of these, A27V and P85A were new. Recombinant variant proteins were prepared using an Escherichia coli expression system, purified, and quantified via CO-difference spectral analysis. The conversion of arachidonic acid to 20-HETE by the coding variants was compared to that of the wild-type protein. Wild-type CYP4F2 exhibited the highest intrinsic clearance, followed by P85A, A27V, V433M, and R47C (40-65% of the wild-type value). The locations of the mutated residues in the three-dimensional protein structure were predicted by structural modeling, and the possible effects on 20-HETE synthesis discussed. In summary, we describe the allele frequency, haplotype distribution, and linkage disequilibrium of CYP4F2 and functionally analyze the CYP4F2 coding variants. Our findings suggest that individuals having the low-activity alleles of CYP4F2 may inefficiently convert arachidonic acid into 20-HETE. This may aid in our understanding of 20-HETE-related blood pressure problems and cardiovascular diseases when genotype-phenotype association studies are performed in the future.
CYP4F2 是一种参与从花生四烯酸形成 20-羟二十碳四烯酸(20-HETE)的酶,并将维生素 K 代谢为无活性形式。我们的目标是鉴定新的 CYP4F2 遗传变异,并表征将花生四烯酸转化为 20-HETE 的功能后果。我们使用直接 DNA 测序鉴定了总共 20 个单核苷酸多态性(SNP),包括在 50 个随机选择的受试者中发现的四个编码变异,A27V、R47C、P85A 和 V433M。其中,A27V 和 P85A 是新的。使用大肠杆菌表达系统制备重组变体蛋白,通过 CO 差光谱分析进行纯化和定量。比较编码变异体将花生四烯酸转化为 20-HETE 的情况与野生型蛋白的情况。野生型 CYP4F2 表现出最高的内在清除率,其次是 P85A、A27V、V433M 和 R47C(野生型值的 40-65%)。通过结构建模预测突变残基在三维蛋白质结构中的位置,并讨论对 20-HETE 合成的可能影响。总之,我们描述了 CYP4F2 的等位基因频率、单倍型分布和连锁不平衡,并对 CYP4F2 编码变异进行了功能分析。我们的研究结果表明,携带 CYP4F2 低活性等位基因的个体可能无法有效地将花生四烯酸转化为 20-HETE。这可能有助于我们在未来进行基因型-表型关联研究时,了解与 20-HETE 相关的血压问题和心血管疾病。